Stroke is the leading cause of disability and the third cause of death in the United States. About 20% of acute ischemic strokes (AIS) are caused by a large artery occlusion, and restoration of blood flow in a reasonable time is the principle goal of treatment. FDA-approved recombinant tissue plasminogen activator (tPA) administration for treatment of stroke is efficacious, but it has short treatment time window and risk of symptomatic hemorrhage that result in only 3–5% patients of who receive this treatment. Alternatively, endovascular treatment using thrombectomy devices, MERCI and Penumbra systems, has been cleared by the FDA. Without adjunctive therapies, the recanalization rate and clinical outcome associated with these devices could be improved.

This content is only available via PDF.
You do not currently have access to this content.